SummaryOur understanding of the pathophysiological mechanisms underlying chronic pain in inflammatory bowel disease is incomplete. Here we show that microbial manipulation modulates the development of visceral, but not somatic, pain in a mouse model of postinflammatory dextran sodium sulfate colitis.

Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are chronic, debilitating illnesses with high socioeconomic burden and increasing prevalence.[@bib1] Despite achieving endoscopic remission, more than 20% of IBD patients experience chronic abdominal pain,[@bib2]^,^[@bib3] which is associated with high levels of anxiety, depression and poor quality of life.[@bib2]^,^[@bib4]^,^[@bib5] Furthermore, studies demonstrate increased prevalence of widespread somatic pain in the absence of inflammation in IBD,[@bib6] indicating altered sensory neural processing in this condition.[@bib3] Unfortunately, effective treatments for chronic pain are severely limited, such that 5%--25% of IBD patients are on chronic narcotic therapy, use of which is not only ineffectual but leads to increased mortality.[@bib3]^,^[@bib7]

The gut microbiome affects a wide variety of gastrointestinal processes.[@bib8] There is evidence that some IBD patients in remission exhibit persistent changes in the microbiome,[@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14] although it is not known whether these changes are a cause or consequence of previous inflammation, dietary changes, or altered gastrointestinal transit.[@bib8] IBD patients in endoscopic remission with chronic pain exhibit elevated rectal transient receptor potential vanilloid-1 receptor (TRPV1) expression, which correlated with the severity of abdominal pain.[@bib15] Interestingly, there is evidence that microbial products can directly stimulate nociceptors[@bib16], [@bib17], [@bib18], [@bib19], [@bib20] via TRP channels,[@bib21] whereas microbial manipulation results in altered function and expression of molecular targets in pain signaling such as TRPV1.[@bib22]^,^[@bib23] This suggests a potential link between dysbiosis and chronic visceral pain in the absence of inflammation in IBD through the microbial modulation of TRP receptors.

Our goal was to examine whether microbial perturbation in the postinflammatory state contributed to persistent visceral hypersensitivity. We chose to use the postinflammatory dextran sodium sulfate (DSS) mouse model of colitis because this is an established animal model of chronic visceral pain, in which animals display increased visceral hypersensitivity 5 weeks after DSS administration in the absence of inflammation.[@bib24] Postinflammatory visceral hyperalgesia was found to be dependent on TRPV1 in this model, because TRPV1 expression in afferent nerves was elevated in the postinflammatory state,[@bib24], [@bib25], [@bib26] similar to IBD patients in endoscopic remission with chronic pain.[@bib15] We also examined somatic pain in this model because of the data demonstrating increased prevalence of non-inflammatory somatic pain in IBD.[@bib6]^,^[@bib27] To manipulate the microbiome, we administered a broad-spectrum antibiotic cocktail to mice[@bib28] and also performed fecal microbial transplant (FMT).[@bib29]^,^[@bib30] We set out to test whether the dysbiotic microbiome in the postinflammatory state drives nociceptor sensitization through TRPV1 regulation and thus may contribute to the transition from acute to chronic pain.

Results {#sec1}
=======

Postinflammatory Microbial Perturbation Leads to Visceral Hyperalgesia But Not Somatic Hypersensitivity {#sec1.1}
-------------------------------------------------------------------------------------------------------

To evaluate the effects of inflammation-induced microbial perturbation on visceral pain, mice were treated with 2.5% DSS in the drinking water for 5 days (DSS) or water alone (control \[CT\]) and allowed to recover for 5 weeks ([Figure 1](#fig1){ref-type="fig"}*A*). These mice were divided into 2 subgroups and treated with antibiotics (Abx) for the last 2 weeks of recovery (CT + Abx; DSS + Abx). Mice exposed to DSS showed signs of clinical disease including significant weight loss ([Figure 1](#fig1){ref-type="fig"}*B*) and loose stools but recovered after 5 weeks and did not exhibit macroscopic or microscopic intestinal inflammation at the time of death, as previously described[@bib24] ([Figure 1](#fig1){ref-type="fig"}*C--E*). Similarly, Abx treatment did not result in any macroscopic inflammation ([Figure 1](#fig1){ref-type="fig"}*C* and *D*).Figure 1**Postinflammatory DSS mice exhibit no signs of macroscopic or microscopic inflammation. (*A*) Experimental protocol.** Colitis was induced using 2.5% DSS for 5 days. Mice were allowed to recover for 3 weeks and then antibiotics (Abx) were administered in drinking water for 2 weeks before death. (*B*) DSS-treated animals initially lose weight but catch up to their control counterparts. Two-way analysis of variance, control (CT) vs DSS, ∗∗∗∗*P* \< .0001; CT vs DSS + Abx, ++++*P* \< .0001. Controls (CT): n = 12, DSS: n = 15, CT + Abx: n = 11, DSS + Abx: n = 10. Macroscopic inflammation was assessed by using colon thickness (*C*) and length (*D*). CT: n = 17, DSS: n = 20, CT + Abx and DSS+ Abx, n = 8. Microscopic inflammation was assessed by myeloperoxidase activity quantification (*E*) between control (n = 10) and DSS (n = 7) groups. DSS, dextran sulfate sodium.

The visceromotor response to colorectal distention was increased in postinflammatory DSS mice when compared with control mice given water only, similar to that seen previously[@bib24] (area under the curve for colorectal distention: control, 0.1 ± 0.01 vs DSS, 0.16 ± 0.01; *P* \< .01; [Figure 2](#fig2){ref-type="fig"}*A*). Microbial disruption with Abx during colitis recovery induced visceral allodynia and hyperalgesia in Abx-treated mice (visceromotor response at 30 mm Hg: control, 0.01 ± 0.03 vs control + Abx, 0.05 ± 0.0; *P* \< .05; area under the curve for colorectal distention: control, 0.1 ± 0.01 vs DSS + Abx, 0.22 ± 0.04; *P* \< .01; [Figure 2](#fig2){ref-type="fig"}*A*), independent of DSS treatment.Figure 2**Postinflammatory DSS mice exhibit both visceral and somatic hyperalgesia.** (*A*) Visceral pain was assessed by using the visceromotor response to colorectal distention. Kruskal-Wallis test of area under the curve: ∗*P* \< .05; ∗∗*P* \< .01. Controls (CT): n = 15, DSS: n = 15, CT + Abx: n = 13, and DSS + Abx: n = 15, 4 experiments). Somatic pain was assessed 7 days before death by using the automated Von Frey (mechanical, *B*) and hot plate tests (thermal, *C*). One-way analysis of variance: ∗∗*P* \< .01; ∗∗∗*P* \< .001, ∗∗∗∗*P* \< .0001 (CT: n = 15, DSS and DSS + Abx: n = 10, CT + Abx: n = 13 for the automated Von Frey test. CT and DSS: n = 15, CT + Abx: n = 16, and DSS + Abx: n = 10 for the hot plate test, 4 experiments). (*D*) Visceromotor responses were tested before and 1 hour after administration of saline (Vehicle, Veh) or antibiotics into the colon via a double-lumen catheter. No differences were noted in visceral sensitivity before or after administration of saline or antibiotics. Abx, antibiotics; DSS, dextran sulfate sodium.

To determine whether microbial manipulation was able to modulate somatic pain, we assessed both mechanical and thermal hypersensitivity in animals treated with DSS and Abx. Mechanical sensitivity was assessed by using the automated Von Frey test in the hind paw, and thermal sensitivity was evaluated by using the hot plate test. Mice treated with DSS developed somatic hyperalgesia in both mechanical (Von Frey test force: control, 7.7 ± 0.24 g vs DSS, 6 ± 0.23 g; *P* \< .0001; control + Abx, 8.1 ± 0.25 g vs DSS + Abx, 6.6 ± 0.19 g; *P* \< .001; [Figure 2](#fig2){ref-type="fig"}*B*) and thermal (time on 52°C hot plate: control, 10.6 ± 0.51 seconds vs DSS, 7.9 ± 0.40 seconds; *P* \< .001; control + Abx, 10.8 ± 0.37 seconds vs DSS + Abx, 7.5 ± 0.40 seconds; *P* \< .0001; [Figure 2](#fig2){ref-type="fig"}*C*) tests independent of Abx treatment.

To evaluate whether Abx exerted a direct effect on visceral pain, Abx were directly administered into the colon, and visceromotor responses were tested before and 1 hour after administration of either vehicle (sterile saline) or Abx into the colon.[@bib31] No differences were seen in visceral sensitivity between groups (area under the curve for colorectal distention: before vehicle: 0.63 ± 0.20, after vehicle: 0.73 ± 0.14, before Abx: 0.59 ± 0.13, after Abx: 0.73 ± 0.14; one-way analysis of variance, *P* = .65; n = 6/group; [Figure 2](#fig2){ref-type="fig"}*D*).

Microbial Reconstitution After Antibiotics Treatment Reverses Changes in Visceral, But Not Somatic, Hyperalgesia {#sec1.2}
----------------------------------------------------------------------------------------------------------------

To assess the role of Abx-induced microbial disruption in visceral pain, Abx-treated animals were given a 2-week washout period in which they were given water only ([Figure 3](#fig3){ref-type="fig"}*A*). Seven weeks after DSS, the visceromotor response to colorectal distention in postinflammatory DSS mice was still significantly higher than controls (area under the curve for colorectal distention: control, 0.07 ± 0.01 vs DSS, 0.15 ± 0.04; *P* \< .05; [Figure 3](#fig3){ref-type="fig"}*B*). Interestingly, visceral hypersensitivity recovered to control levels in control + Abx and DSS + Abx mice after 2 weeks of Abx washout. However, somatic hyperalgesia was unaffected by Abx washout ([Figure 3](#fig3){ref-type="fig"}*C* and *D*; Von Frey test force: control, 7.4 ± 0.16 g vs DSS, 5.5 ± 0.11 g; *P* \< .001; control + Abx, 7.2 ± 0.27 g vs DSS + Abx, 5.8 ± 0.12 g; *P* \< .001; time on 52°C hot plate: control, 13 ± 0.8 seconds vs DSS, 10.2 ± 0.6 seconds; *P* \< .05; control + Abx, 13.9 ± 0.71 seconds vs DSS + Abx, 10.2 ± 0.34 seconds; *P* \< .01), suggesting that microbial manipulation modulates the development of visceral, but not somatic, pain.Figure 3**Microbial recovery after antibiotic administration reverses changes in visceral hyperalgesia. (*A*) Experimental protocol.** Colitis was induced by using 2.5% DSS for 5 days, and animals were allowed to recover. Antibiotics (Abx) were administered in drinking water from days 28--42; animals were then given a 2-week washout period. (*B*) Visceral pain was assessed by using the visceromotor response to colorectal distention. One-way analysis of variance of area under the curve of DSS vs CT: ∗*P* \< .05. CT: n = 11, CT + Abx and DSS: n = 12, DSS + Abx: n = 15. Somatic pain was assessed by using the automated Von Frey (*C*) and hot plate (*D*) tests. One-way analysis of variance: ∗*P* \< .05; ∗∗*P* \< .01; ∗∗∗*P* \< .001; ∗∗∗∗*P* \< .0001. CT and DSS: n = 7; CT + Abx and DSS + Abx: n = 8 for automated Von Frey test and n = 14/group for hot plate test (4 experiments). CT, control; DSS, dextran sulfate sodium.

Gut Microbiota and Stool Short-Chain Fatty Acid Content Differ Between Control and Postinflammatory Dextran Sulfate Sodium Mice {#sec1.3}
-------------------------------------------------------------------------------------------------------------------------------

Microbes and bacterial metabolites such as short-chain fatty acid (SCFA) are known to activate intestinal epithelial cells and extrinsic spinal neurons,[@bib16], [@bib17], [@bib18], [@bib19]^,^[@bib32]^,^[@bib33] suggesting that they may play a role in visceral hypersensitivity. Stool was collected from mice at baseline and at the time of death for microbial composition and SCFA analysis.

Examination of the microbiome composition demonstrated that the alpha and beta diversity were not significantly different when comparing control and postinflammatory DSS mice at the 5-week recovery time point, whereas Abx treatment resulted in a marked disruption characterized by a shift in both alpha and beta diversity at the operational taxonomic unit level (n = 6/group except DSS + Abx baseline, n = 7; control baseline, n = 5; and DSS + Abx group at death, n = 4; alpha diversity: linear mixed-effects model, *P* = .0072; beta diversity: permutational multivariate analysis of variance, *P* \< .001; [Figure 4](#fig4){ref-type="fig"}*A* and *B*). When compared at the phylum and genus levels, the composition of all 4 groups was similar at baseline ([Figure 4](#fig4){ref-type="fig"}*C*). As expected, Abx treatment resulted in profound shifts in the microbiota characterized by an overgrowth of proteobacteria, primarily *Klebsiella* species ([Figure 4](#fig4){ref-type="fig"}*C*; beta-binomial regression, *P* \< .01). Examined at the 5-week recovery period, DSS treatment resulted in a relative decrease in Bacteroidetes and an increase in Firmicutes phylum compared with controls, as previously described[@bib34] ([Figure 4](#fig4){ref-type="fig"}*D*); in addition, an increase in *Verrucomicrobia*, which has been linked with gut health in some studies,[@bib35]^,^[@bib36] was seen over time in controls. At the genus level, a significant increase in *Lachnospiraceae* NK4A136 and FCS020 groups as well as *Ruminococcus* was seen, whereas a significant decrease in *Akkermansia*, *Alistipes*, *Muribaculaceae*, *Ruminococcacaea*, and *Bacteroides* species was apparent in postinflammatory DSS mice when compared with controls ([Figure 4](#fig4){ref-type="fig"}*D*; beta-binomial regression, *P* \< .01). After antibiotic washout ([Figure 3](#fig3){ref-type="fig"}*A*), there was partial recovery of the microbiome in Abx-treated mice ([Figure 5](#fig5){ref-type="fig"}*A* and *B*) at the 7-week time point. However, DSS treatment resulted in a persistent increase in *Lachnospiraceae* NK4A136 and FCS020 groups as well as *Ruminococcus* groups at the 7-week time point ([Figure 5](#fig5){ref-type="fig"}*C*) when compared with controls*.*Figure 4**Postinflammatory DSS mice exhibit changes in the microbiome.** The alpha (*A*) and beta (*B*) diversity was assessed in controls, postinflammatory DSS, and antibiotic-treated mice. Baseline samples were not different; antibiotic treatment caused significant shifts in both alpha (linear mixed-effects model, *P* = .0072) and beta diversity (permutational multivariate analysis of variance, *P* \< .001). *Points* represent individual samples, *lines* represent the median, and *crosses* represent the mean. (*C*) Relative abundance of different phyla at baseline (B) and sacrifice (S) time points. No significantly different phyla were seen at baseline between groups. (*D*) Comparison of bacterial content at the genus level between control and postinflammatory DSS mice at the sacrifice time point. *Blue symbols* represent families significantly increased in the postinflammatory DSS mice, and *red symbols* represent families significantly increased in controls (beta-binomial regression model, *P* \<.01). N = 6/group, except DSS + Abx baseline, n = 7, control baseline, n = 5, and DSS + Abx group at sacrifice, n = 4. Abx, antibiotics; DSS, dextran sulfate sodium.Figure 5**Postinflammatory DSS mice exhibit persistent changes in the microbiome.** The alpha (*A*) and beta (*B*) diversity was assessed in controls, postinflammatory DSS, and mice given antibiotics and then allowed a 2-week washout period. Baseline samples were not different; antibiotic washout allowed some degree of microbial recovery, although there was still a significant difference in the alpha diversity when comparing CT vs CT + Abx groups (Tukey honestly significant difference; *P* = .0067) and in beta diversity when comparing CT vs CT + Abx groups and DSS vs DSS + Abx groups (permutational multivariate analysis of variance, CT vs CT + Abx, *P* = .001; DSS vs DSS + Abx, *P* = .003). *Points* represent individual samples, *lines* represent the median, and *crosses* represent the mean. (*C*) Comparison of bacterial content at the genus level between control and postinflammatory DSS mice at the washout time point. *Blue symbols* represent families significantly increased in the post-inflammatory DSS mice, and *red symbols* represent families significantly increased in controls (beta-binomial regression model, *P* \< .01). N = 6--8/ group. Abx, antibiotics; CT, control; DSS, dextran sulfate sodium.

The subtle microbial perturbation observed in postinflammatory DSS mice was associated with an increase in fecal acetate (acetate \[mmol/L\]: control, 2.2 ± 0.02 vs DSS, 4.4 ± 0.1; *P* \< .05) and butyrate (butyrate \[mmol/L\]: control, 1 ± 0.02 vs DSS, 2.3 ± 0.04; *P* \< .05) but not propionate when compared with controls ([Figure 6](#fig6){ref-type="fig"}*A*). SCFA concentration was below the limit of detection in Abx-treated animals. After antibiotic washout, SCFA concentration in Abx-treated animals was detectable but significantly lower for butyrate and propionate compared with the control and DSS groups, respectively ([Figure 6](#fig6){ref-type="fig"}*B*), suggesting partial restoration after Abx washout. No differences were observed between control and DSS groups.Figure 6**Postinflammatory DSS mice exhibit elevated stool short-chain fatty acids.** (*A*) Stool short-chain fatty acid content in postinflammatory DSS mice and controls. In antibiotic-treated animals (Abx), short-chain fatty acid concentration was below the limit of detection for butyrate and propionate. N = 6/group. (*B*) Stool short-chain fatty acid content after 2 weeks of antibiotic washout. CT and CT + Abx: n = 7, DSS and DSS + Abx: n = 6. One-way analysis of variance: ∗*P* \< .05; ∗∗*P* \< .01. Abx, antibiotics; CT, control; DSS, dextran sulfate sodium.

Fecal Microbial Transplantation of Postinflammatory Dextran Sulfate Sodium Microbiota Transfers the Phenotype of Visceral, But Not Somatic, Pain {#sec1.4}
------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether the dysbiotic microbiome was necessary for the expression of visceral hypersensitivity, we performed FMT experiments. Mice were treated with 2 weeks of Abx before FMT to disrupt the basal microbiome ([Figure 7](#fig7){ref-type="fig"}*A*). Twenty-four hours after the cessation of Abx, mice received 4 days of oral gavage with homogenized stool derived from control mice, postinflammatory DSS mice, or vehicle alone (phosphate-buffered saline \[PBS\] + glycerol). Animals treated with postinflammatory DSS stools developed visceral hypersensitivity compared with mice given vehicle or control stool (area under the curve for colorectal distention: FMT PBS, 0.06 ± 0.007 vs FMT DSS, 0.12 ± 0.02; *P* \< .01; FMT control, 0.05 ± 0.006 vs FMT DSS, 0.12 ± 0.02; *P* \< .001; [Figure 7](#fig7){ref-type="fig"}*B*). Interestingly, mice given vehicle displayed hyperalgesia at 60 mm Hg compared with mice given control stool (visceromotor response at 60 mm Hg: FMT control, 0.03 ± 0.004 vs FMT PBS, 0.06 ± 0.007; *P* \< .05; [Figure 7](#fig7){ref-type="fig"}*B*), suggesting that the sensitizing effect of Abx alone on visceral sensitivity could be reversed by FMT from control mice. In contrast, FMT did not transfer somatic hypersensitivity observed in postinflammatory mice ([Figure 7](#fig7){ref-type="fig"}*C* and *D*), suggesting that the microbiome plays a central role in the pathogenesis of postinflammatory visceral, but not somatic, hypersensitivity.Figure 7**Fecal microbial transplant of postinflammatory DSS stool transfers the phenotype of visceral but not somatic pain and is associated with increased stool short-chain fatty acids.** (*A*) Experimental protocol. Antibiotic-treated recipient animals received stool via gavage from postinflammatory DSS mice, controls (CT), or vehicle (sterile phosphate-buffered saline + glycerol) alone. (*B*) Visceral pain was increased in mice given postinflammatory DSS stool when compared with control and vehicle. Vehicle: n = 10, CT: n = 7, DSS: n = 11, 2 experiments. One-way analysis of variance of area under the curve: ∗∗*P* \< .01; ∗∗∗*P* \< .001. Mice given vehicle displayed hyperalgesia at 60 mm Hg compared with mice given control stool (two-way analysis of variance, ^⍵^*P* \< .05). Somatic pain, assessed by using automated Von Frey (*C*) and hot plate tests (*D*), was unaffected after fecal microbial transplant. Vehicle: n = 9, CT: n = 7, DSS: n = 8, 2 experiments. (*E*) Fecal butyrate and propionate are increased in the stool of recipient mice given stool from postinflammatory DSS animals when compared with those that received stool from controls or vehicle. Vehicle: n = 12, CT: n = 7, DSS: n = 11. ∗∗*P* \< .01; ∗∗∗*P* \< .001; ∗∗∗∗*P* \< .0001. DSS, dextran sulfate sodium.

Examination of the SCFA profile of recipient mice revealed that FMT was associated with an increase in fecal propionate (propionate \[mmol/L\]: FMT PBS, 0.147 ± 0.044 vs FMT DSS, 0.6 ± 0.087; *P* \< .0001; FMT control, 0.337 ± 0.041 vs FMT DSS, 0.6 ± 0.087; *P* \< .05) and butyrate (butyrate \[mmol/L\]: FMT PBS, 0.073 ± 0.028 vs FMT DSS, 0.509 ± 0.103; *P* \< .001; FMT control, 0.144 ± 0.021 vs FMT DSS, 0.509 ± 0.103; *P* \< .01) in the stool of recipients given postinflammatory DSS stool compared with those given vehicle or control stool ([Figure 7](#fig7){ref-type="fig"}*E*). These data suggest that postinflammatory visceral hypersensitivity is associated with microbial shifts resulting in an increase in fecal SCFA, in particular butyrate.

Supernatant From Postinflammatory Dextran Sulfate Sodium Mice Colon Increases Transient Receptor Potential Vanilloid-1 Receptor Function in Naive Dorsal Root Ganglion {#sec1.5}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

To evaluate in vitro correlates of nociceptor activation, we assessed the function of cultured mouse dorsal root ganglion (DRG) neurons expressing TRPV1 and transient receptor potential ankyrin-1 receptor (TRPA1) using calcium imaging and examined responses to the TRPV1 agonist, capsaicin, and the TRPA1 agonist, mustard oil.[@bib37], [@bib38], [@bib39] We incubated cultured T9-L2 (colonic projecting)[@bib40]^,^[@bib41] DRG neurons with sterile-filtered colonic supernatants, derived from a total of 6 mice, 5 weeks after DSS or control administration ([Figure 1](#fig1){ref-type="fig"}*A*). Thus, we exposed naive TRP-expressing DRG neurons to the nociceptive mediators present in the colon.[@bib39] TRPV1 responses to 100 nmol/L capsaicin stimulation were significantly increased in naive colonic DRGs incubated with colonic supernatant derived from postinflammatory DSS mice compared with controls (area under the curve capsaicin 100 nmol/L: control, 202.4 ± 15.9 vs DSS, 309.8 ± 26.5; *P* \< .05) ([Figure 8](#fig8){ref-type="fig"}*A*). In contrast, TRPA1 responses to mustard oil were not different between groups ([Figure 8](#fig8){ref-type="fig"}*B*). We also evaluated responses to capsaicin and mustard oil in hind paw projecting[@bib42] L4-L5 DRG neurons from postinflammatory DSS mice. TRPV1 responses in L4-L5 DRGs from DSS and DSS + Abx treated mice were significantly increased in response to 100 nmol/L capsaicin compared with control mice (area under the curve capsaicin 100 nmol/L: control, 99.5 ± 9.2 vs DSS, 133.4 ± 16.1; control, 99.5 ± 9.2 vs DSS + Abx, 128.5 ± 6.7; *P* \< .05) ([Figure 8](#fig8){ref-type="fig"}*C*). No differences were observed in TRPA1 agonist responses between groups ([Figure 8](#fig8){ref-type="fig"}*D*).Figure 8**SCFAs modulate TRPV1 sensitization in dorsal root ganglia (DRGs) neurons.** T9-L2 DRGs from naive mice (n = 6/group) were cultured overnight with supernatants from CT, Abx-treated, and DSS-treated mice. Cells were stimulated with the TRPV1 (*A*) or TRPA1 (*B*) agonists, capsaicin (100 nmol/L) or mustard oil (100 nmol/L), respectively, and calcium imaging was used to evaluate TRPV1 or TRPA1 sensitization. L4-L5 DRGs from postinflammatory mice (n = 6/group) were cultured overnight. (*C*) Capsaicin (100 nmol/L) or (*D*) mustard oil (100 nmol/L) was used to evaluate TRPV1 or TRPA1 sensitization using calcium imaging. (*E*) T9-L2 dorsal root ganglia (n = 6/group) were incubated directly with the short-chain fatty acids acetate (5 mmol/L), butyrate (1 mmol/L), or propionate (1 mmol/L). Cells were stimulated with capsaicin (100 nmol/L), and calcium imaging was used to evaluate TRPV1 sensitization. One-way analysis of variance of area under the curve, ∗*P* \< .05 (3 experiments). Abx, antibiotics; CT, control; DSS, dextran sulfate sodium; TRPA1, transient receptor potential ankyrin-1 receptor; TRPV1, transient receptor potential vanilloid-1 receptor.

Because fecal butyrate content was significantly elevated in the stool of postinflammatory DSS mice, as well as in recipient mice given postinflammatory DSS stool, we investigated the direct effect of SCFA on TRPV1 sensitization. Naive colonic DRG neurons were incubated with sodium acetate (5 mmol/L), sodium butyrate (1 mmol/L), and sodium propionate (1 mmol/L), and responses to capsaicin were examined. TRPV1 responses were increased in the presence of sodium butyrate and sodium propionate but not sodium acetate (area under the curve capsaicin 100 nmol/L: control, 136.7 ± 5.9 vs butyrate, 174.9 ± 11.2; control, 136.7 ± 5.9 vs propionate, 169 ± 7.2) ([Figure 8](#fig8){ref-type="fig"}*E*) when compared with media alone, suggesting that microbial-derived soluble mediators modulate TRP sensitization.

Discussion {#sec2}
==========

IBD patients in endoscopic remission with chronic abdominal pain display decreased pain thresholds when compared with healthy controls,[@bib43]^,^[@bib44] suggesting activation of pro-nociceptive pathways and/or suppression of anti-nociceptive pathways in these patients. It is well-known that the gut microbiome plays a key role in the pathogenesis of IBD[@bib8]; however, the role of the microbiome in the development of chronic visceral pain in IBD is poorly understood. We have demonstrated that microbial manipulation, through the use of Abx or FMT in the postinflammatory DSS mouse, modulates the development of visceral, but not somatic, pain. SCFA-producing species and fecal SCFA content were increased in postinflammatory DSS mice, whereas incubation of cultured DRG neurons with SFCAs in vitro leads to sensitization of TRPV1, suggesting that microbial-derived soluble products such as SCFA are able to sensitize nociceptive neurons.

Chronic visceral pain is a disorder of the gut-brain axis, and both central and peripheral mechanisms contribute to its pathogenesis.[@bib3] Painful sensation from the gut is relayed to the central nervous system by polymodal nociceptors, which transduce mechanical and chemical stimuli.[@bib45] TRPV1 is expressed on a subset of nociceptive peptidergic neurons and transduces inflammatory injury.[@bib45] TRPV1 stimulation has been shown to participate in the generation of neuropathic pain in IBD by provoking the release of neuropeptides such as substance P and calcitonin gene-related peptide from peripheral terminals.[@bib26]^,^[@bib46] In conjunction with other inflammatory mediators released during injury or infection, neuropeptides have immunoregulatory properties and can in turn increase nociceptor excitability.[@bib45]^,^[@bib46] Thus, TRPV1 sensitization is instrumental in the generation of inflammatory hyperalgesia, or exaggerated pain responses, and allodynia, or pain caused by innocuous stimuli.[@bib45] Furthermore, TRPV1 expression is increased in both patients with acute flares of IBD and experimental models of acute colitis,[@bib26]^,^[@bib47] as well as in IBD patients with chronic abdominal pain and endoscopic remission.[@bib15] Because of the pivotal importance of TRPV1 in pain in IBD, we chose to use the postinflammatory DSS mouse model where TRPV1 sensitization was shown to play a crucial role in the generation of chronic postinflammatory visceral pain.[@bib24]

We found that in vitro incubation of naive cultured T9-L2 DRG neurons (colonic projecting[@bib40]^,^[@bib41]) with supernatants from postinflammatory DSS mice, but not supernatants from Abx-treated animals, resulted in increased intracellular calcium in response to TRPV1 stimulation with capsaicin. Furthermore, stimulation of L4-L5 DRGs (hind paw projecting[@bib42]) derived directly from postinflammatory DSS mice with capsaicin also resulted in increased intracellular calcium responses when compared with neurons derived from Abx-treated mice alone. This parallels our in vivo data where previous inflammation resulted in somatic and visceral pain. Abx treatment induced visceral hyperalgesia alone; this effect was reversed by a 2-week antibiotic washout period. These data suggest that Abx treatment and previous inflammation cause visceral hyperalgesia through different mechanisms. It should be noted that we did not use retrograde tracers to specifically evaluate colonic projecting neurons, because this technique requires additional surgery/anesthesia and adds increased stress to mice, which itself could lead to visceral pain.[@bib48]^,^[@bib49] Previous studies have demonstrated that incubation of naive cultured T9-L2 DRG neurons with sterile-filtered colonic supernatants results in similar findings to direct assessment of colonic projecting neurons.[@bib50]

Postinflammatory DSS mice exhibited somatic as well as visceral hyperalgesia, demonstrating both mechanical and thermal hyperalgesia in our model. This was not affected by Abx treatment. Similarly, FMT of postinflammatory DSS stool did not result in the transfer of somatic hyperalgesia when compared with control stool or vehicle, suggesting that microbial manipulation does not modulate somatic hyperalgesia. Instead, our data support the idea that the somatic hyperalgesia in our model results from the initial inflammatory insult and is maintained centrally. There is evidence that somatic hyperalgesia results from central sensitization in visceral pain models.[@bib22]^,^[@bib25]^,^[@bib51], [@bib52], [@bib53] For example, mice given DSS for 7 days were shown to display increased neuronal activation in the spinal cord, thalamus, hypothalamus, amygdala, and prefrontal cortex in a previous study.[@bib54] This was associated with mechanical and thermal hyperalgesia of the plantar skin in mice, suggesting that acute colitis caused central sensitization, which then resulted in somatic hyperalgesia.[@bib54] In another study of postinflammatory DSS mice, capsaicin instillation in the colon caused neuronal activation in the dorsal horn, which correlated with somatic hyperalgesia of the abdominal wall, suggesting that in the postinflammatory model, referred somatic pain was secondary to central sensitization.[@bib25] A study in rats demonstrated that broad-spectrum Abx use did not result in thermal hyperalgesia,[@bib22] similar to our own data. Conversely, chemotherapy-induced mechanical hyperalgesia was reduced in Abx-treated as well as germ-free mice.[@bib55] In another study that examined somatic hyperalgesia, broad-spectrum Abx treatment alone resulted in mechanical hyperalgesia to the von Frey hair test and the tail-flick test in rats.[@bib56] Taken together, these data suggest that although central sensitization may underlie somatic pain in the postinflammatory state, any role of the microbiome in this phenomenon needs to be examined more closely.

It was striking that Abx treatment alone results in profound visceral hyperalgesia. Metronidazole and neomycin in particular are known to have neurotoxic and ototoxic effects[@bib57], [@bib58], [@bib59]; however, visceromotor responses were unchanged after direct catheter infusion of Abx vs vehicle, suggesting that responses in Abx-treated animals were not solely due to neurotoxicity. Previous studies of Abx-treated animals have also found increased visceral pain after Abx treatment. In a seminal study where mice were treated with a 10-day course of oral Abx, animals developed hyperalgesia to colorectal distention, which was associated with increased colonic substance P expression.[@bib31] In a study where neonatal mice were treated with 10 days of Abx, animals developed persistent visceral pain at 10 weeks of age.[@bib60] Interestingly, this was associated with decreased TRPV1 expression in the lumbosacral spinal cord; no evidence of inflammation was seen.[@bib60] Conversely, when adult mice were treated with 6 weeks of broad-spectrum Abx, visceral pain to colorectal distention was markedly attenuated, and this was also associated with decreased TRPV1 expression in the lumbosacral spinal cord.[@bib22] Consistent with these data, germ-free mice displayed visceral hyperalgesia to colorectal distention, an effect that was reversed by bacterial colonization; TRPV1 expression was unchanged in this model.[@bib61] Together, these data suggest that commensal microbes may be anti-nociceptive; Abx treatment or absence of the microbiome seems to abrogate these anti-nociceptive effects. Indeed, probiotics, such as *Lactobacillus* and *Bifidobacterium* species, have been shown to decrease the visceromotor response to colorectal distention in animal models[@bib31]^,^[@bib62]; the probiotic *Lactobacillus reuteri DSM 17938* was able to decrease the capsaicin-induced increase in intracellular calcium in rat DRG neurons and reduce the response of distention evoked firing of spinal nerves, an effect that was abolished in TRPV1 knockout mice.[@bib63] *Faecalibacterium prausnitzii*, a butyrate-producing member of the Firmicutes phyla, was found to decrease the excitability of DRG neurons through a protease-dependent mechanism.[@bib19] In the current study, we observed that Abx-induced visceral hypersensitivity and dysbiosis were independent of SCFAs, whereas microbial shifts in the postinflammatory DSS model and subsequent visceral hypersensitivity were dependent on SCFA and TRPV1 sensitization. Thus, it is possible that Abx treatment results in dysbiosis and the loss of anti-nociceptive species/soluble mediators, resulting in visceral hyperalgesia.

Postinflammatory DSS mice exhibited microbial shifts in our study, with a relative decrease in Bacteroidetes and an increase in the Firmicutes phyla; close examination at the genus level revealed a relative increase in SCFA-producing species such as *Lachnospiraceae* and *Ruminococcus*. SCFAs such as butyrate are a crucial source of energy for colonocytes and are important in maintaining gut barrier integrity and inhibiting inflammation.[@bib20]^,^[@bib64] Our data are in agreement with a previous study that examined the microbiota after 3 cycles of DSS in mice, which also found an increase in Lachnospiraceae species.[@bib34] The increase in SCFA-producing Firmicutes is in marked contrast to the microbial profile of patients with active IBD,[@bib9]^,^[@bib65], [@bib66], [@bib67] where a loss of these SCFA-producing species is more common. However, some patients with irritable bowel syndrome (IBS), a disorder of the brain-gut axis characterized by abdominal pain and altered bowel habits in the absence of overt inflammation,[@bib68] exhibit a similar increase in SCFA-producing species, in particular *Lachnospiraceae*,[@bib69]^,^[@bib70] although this finding has not been universal, likely because of the heterogeneous nature of IBS.[@bib71] Interestingly, increased *Lachnospiraceae* species have been noted in the microbiota derived from the stool of both adults[@bib72], [@bib73], [@bib74] and children with IBS,[@bib75] and this increase was correlated with visceral pain[@bib72]^,^[@bib75] and the activation of brain regions involved in the processing of painful sensorimotor input,[@bib72] suggestive of a causal relationship between this family of bacteria and visceral pain.

In our study, incubation of cultured naive DRG neurons with the SCFAs butyrate and propionate resulted in TRPV1 sensitization, whereas FMT of postinflammatory DSS stool resulted in a further increase in visceral hyperalgesia when compared with Abx alone. This suggests that in the postinflammatory DSS model, the microbiome may be pro-nociceptive. It should be noted that colonic supernatants contain soluble factors derived from both the host and the microbiota; hence, we performed experiments where naive DRG neurons were incubated with SCFA alone. This SCFA concentration was chosen on the basis of the quantification data from mouse stool. The evaluation of fecal SCFA levels is well-described[@bib76], [@bib77], [@bib78], [@bib79]; however, it should be noted that fecal/luminal SCFA concentration reflects a dynamic balance between SCFA production and absorption and may not necessarily reflect the true SCFA concentration at the mucosal barrier.[@bib80]^,^[@bib81] As such, these levels should be interpreted with caution. To date, there have been conflicting findings on the role of SCFAs, and in particular butyrate, in visceral pain. Our findings are in agreement with previous data from a rat model where butyrate enemas induced visceral hypersensitivity in control rats through activation of a mitogen-activated protein kinase--dependent mechanism in DRG neurons.[@bib82] Interestingly, in a rat model of acute colitis, butyrate enemas prolonged the pro-nociceptive effect of acute colitis on visceral pain.[@bib83] Furthermore, use of the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low FODMAP) diet, which is effective for the treatment of abdominal pain in IBD patients in remission, results in decreased fecal SCFA content.[@bib77] In contrast with our data, butyrate enemas in healthy patients and mouse models caused a dose-dependent reduction of abdominal pain to colorectal distention.[@bib33]^,^[@bib84] Other studies that used Abx to modulate the microbiome, including our own, demonstrate a decrease in fecal butyrate content associated with an increase in pain behaviors,[@bib22]^,^[@bib85]^,^[@bib86] suggesting that although butyrate may be pro-nociceptive in some model systems, broad-spectrum Abx treatment results in a nonspecific loss in anti-nociceptive bacteria/soluble mediator(s). SCFAs exert their actions through both receptor-mediated and receptor-independent mechanisms.[@bib64] Future pharmacologic and genetic studies should focus on the mechanism whereby SCFAs cause nociceptor sensitization in postinflammatory DSS mice, which will in turn shed light on some of the conflicting data in the literature.

In conclusion, we have demonstrated that the microbiome appears to play an important role in postinflammatory visceral, but not somatic, hypersensitivity. Microbial-derived soluble products, including sodium butyrate and sodium propionate, were able to sensitize nociceptive neurons in vitro, suggesting that these SCFAs may play a role in the pathogenesis of postinflammatory visceral pain.

Materials and Methods {#sec3}
=====================

Animals {#sec3.1}
-------

Six-week-old male C57BL/6 mice were obtained from Charles River Laboratories (Montreal, Quebec, Canada). All mice were housed in plastic sawdust floor cages under standard conditions with free access to drinking water and food. All experiments were conducted on age-matched animals under protocols approved by the University of Calgary Animal Care Committee and in accordance with the guidelines for the ethical use of animals in research of the Canadian Council on Animal Care (AC16-0105). All animals were allowed to acclimatize for 1 week before any experimentation.

Induction of Inflammation and Microbial Manipulation {#sec3.2}
----------------------------------------------------

Colonic inflammation was induced by administration of 2.5% (wt/vol) DSS (36,000--50,000 MW; MP Biochemicals, Solon, OH) in drinking water for 5 days. Mice were separated into 2 groups, control untreated and DSS treated, and were allowed to recover for 5 weeks before the evaluation of visceral hyperalgesia.[@bib24] To manipulate the microbiome, mice received an Abx cocktail consisting of ampicillin, neomycin, metronidazole (1 g/L), and vancomycin (0.5 g/L)[@bib31]^,^[@bib60] (all from Sigma-Aldrich Canada, Oakville, ON, Canada) administered in drinking water 2 weeks before the end of the recovery period. In some cases, mice were allowed to recover for a further 2 weeks after the discontinuation of Abx. Weight changes were measured daily in all mice. Colonic length and thickness were assessed at the time of death as previously described.[@bib24]

Microbial manipulation was also performed by using FMT. Fresh fecal pellets from 6 donor mice were collected, pooled, and weighed. Pellets were homogenized for 5 minutes in 1 mL sterilized PBS supplemented with 10% glycerol by using 1 mm zirconium oxide beads (NextAdvance, Troy, NY) in a 4°C cold room using a bullet blender (NextAdvance). The volume was adjusted to give a concentration of 80 mg feces/mL. The fecal matter was centrifuged for 1 minute at 400*g*, and the supernatant was used for FMT. Recipient mice were pretreated with the previously described Abx cocktail to disrupt the basal microbiome. Subsequently, Abx-treated mice received 80 mg/mL homogenized stool in 200 μL sterile saline + 10% glycerol or sterile saline + 10% glycerol alone for 4 days via orogastric gavage.[@bib29]^,^[@bib30]

In Vivo Measurement of Somatic and Visceral Pain {#sec3.3}
------------------------------------------------

### Visceromotor response to colorectal distention {#sec3.3.1}

The visceromotor response to colorectal distention was assessed as previously described.[@bib24] Briefly, 2 days before colorectal distention, mice were anesthetized with xylazine and ketamine, and electrodes were implanted bilaterally into the abdominal external oblique musculature (Bioflex AS-631; Cooner Wire, Chatsworth, CA). Electrodes were exteriorized at the back of the neck and protected by a plastic tube attached to the skin. Mice were allowed to recover for 48 hours after electrode implantation. For recording, electrodes were connected to a Bio Amplifier, which was then connected to an electromyogram acquisition system (both from ADInstruments, Colorado Springs, CO). A 10.5-mm-diameter balloon catheter (Fogarty arterial embolectomy catheter, 4F; Vygon USA, Lansdale, PA) was gently inserted into the rectum to a depth of 5 mm. Ten-second distentions were performed at pressures of 15, 30, 45, and 60 mm Hg by inflating the balloon in a stepwise fashion with water (20, 40, 60 and 80 μL, respectively) with 5-minute rest intervals. The electromyographic activity of the abdominal muscles was recorded, and visceromotor responses were calculated by using LabChart 7 software (ADInstruments).

To evaluate whether Abx exerted direct effects on visceral sensitivity, Abx or sterile saline (vehicle) were administered directly into the colon via a double lumen catheter, similar to a previous study.[@bib31] Visceromotor responses were tested before and 1 hour after administration of saline or Abx.

### Somatic pain assessment {#sec3.3.2}

Somatic pain evaluation was performed by a blinded investigator. Mechanical and thermal sensitivities were tested simultaneously in all groups on the same day.

### Mechanical sensitivity {#sec3.3.3}

Mechanical sensitivity was tested by measuring the threshold to withdrawal applied to the paw using the automated Von Frey hair test (Ugo Basile, Gemonio, Italy) as described.[@bib87] Mice were individually placed in custom-made plastic compartments on a metallic mesh for 1 hour, 2 days before testing, to minimize stress reactions. On the day of the experiment, 8 mice were allowed to habituate in individual opaque compartments until exploratory behavior was no longer observed (∼20--30 minutes). The hind paw withdrawal threshold was measured by applying a small metal filament that automatically exerts constant progressive pressure perpendicular to the middle of the plantar surface of the hind paw until withdrawal. The force and latency values were recorded. This was repeated 5 times, and each trial was followed by a 10-minute resting period. In each animal, the left or right hind paw was chosen at random, and the withdrawal threshold was measured in all animals in a row, followed by evaluation of the opposite hind paw.

### Thermal sensitivity {#sec3.3.4}

Thermal sensitivity was assessed by using the hot plate test[@bib87] (Bioseb, Pinellas Park, FL). Immediately after the automated Von Frey test, mice were placed on a metal hot plate set to 52°C ± 0.5°C. The latency from placement of the mouse on the heated surface until the first overt behavioral sign of nociception, such as lifting or licking a hind paw, vocalization, or jumping, was measured. The timer was stopped, and the mouse was immediately removed from the hot plate after responding or after a maximum cutoff of 20 seconds to prevent tissue damage.

In Vitro Evaluation of Somatic and Visceral Pain {#sec3.4}
------------------------------------------------

### Supernatant generation {#sec3.4.1}

Colonic supernatants were generated as previously described.[@bib37]^,^[@bib88] Briefly, full circumference colonic tissue sections of 5 mm from all mice used for somatic and visceral pain experiments were transferred and incubated for 1 hour in 96-well plate containing 300 μL Hanks' balanced salt solution (HBSS) supplemented with calcium chloride and magnesium chloride (Gibco, Carlsbad, CA) in a humidified incubator at 37°C under 95% air and 5% CO~2~; samples were not standardized to the weight of segments. Supernatants were filtered (0.2 μm pore polyethersulfone membrane) and stored at −80°C. For in vitro experiments involving calcium imaging, pooled supernatants derived from mice in the same treatment group were used. Pooled supernatants from 2 animals of the appropriate treatment group were used for calcium imaging for each experiment, where naive DRGs were imaged from 2 mice at a time. Three total experiments were performed; naive DRGs from a total of 6 mice were used for the calcium imaging. These DRGs were incubated with pooled supernatants derived from a total of 6 different animals from the appropriate treatment group.

Dorsal Root Ganglion Dissection and Culture {#sec3.5}
-------------------------------------------

Culture of isolated DRG neurons was performed as previously described.[@bib24]^,^[@bib37] Mice were killed by an overdose of ketamine and xylazine, followed by cervical transection. The spinal cord was removed, and the DRGs from T9 to L2 were dissected and removed, because these levels receive nociceptive input from the colon.[@bib40]^,^[@bib41] For assessment of somatic nociceptive input, L4-L5 DRGs, which receive nociceptive input from the hind paw,[@bib42] were dissected. Isolated DRGs were incubated at 37°C in HBSS containing 5100 U/mL Type 1 collagenase (Gibco) and 7.1 U/mL dispase II (Roche, Mannheim, Germany). DRGs were washed in Dulbecco modified Eagle medium (DMEM) (Gibco) containing 10% fetal calf serum, and ganglia were then triturated with a fire-polished Pasteur pipette. Dispersed neurons were suspended in 1 mL DMEM containing 10% fetal bovine serum, 1% penicillin/streptomycin, and 100 ng/mL nerve growth factor (Corning, Tewksbury, MA). The cell suspension was plated onto laminin-coated coverslips (Corning) and stored in a humidified incubator at 37°C under 95% air and 5% CO~2~. After 3 hours, the medium was replaced. For experiments involving colonic supernatants, cells were pretreated overnight with 500 μL supernatant (diluted ½ in DMEM containing 10% fetal bovine serum and 1% penicillin/streptomycin); supernatants from 2 mice within the same group were pooled for each experiment as described above. For experiments involving SCFAs, sodium acetate (5 mmol/L), sodium butyrate (1 mmol/L), and sodium propionate (1 mmol/L) (all from Sigma) were diluted in DMEM and incubated overnight with cultured DRGs. The pH of the medium was not significantly altered in the presence of these SCFAs (pH 7.3--7.5).

Calcium Imaging {#sec3.6}
---------------

Calcium imaging was performed as previously described.[@bib39] Cultured DRGs were imaged by using a 10× objective on an Olympus IX51 microscope controlled by cellSens software (Olympus Canada, Toronto, ON, Canada). Cultured DRG neurons were loaded in HBSS (Gibco) with 2 μmol/L Fura-2AM (Life Technologies, Carlsbad, CA) for 30 minutes at 37°C and then washed with HBSS for 20 minutes at 37°C. The recording chamber was continually perfused at 37°C with external solution (in mmol/L: 140 NaCl, 5 KCl, 10 HEPES, 10 glucose, 1 MgCl~2~, 2 CaCl2; pH adjusted to 7.3--7.4 with 10N NaOH). To examine TRPV1 or TRPA1 activity, cells were perfused with doses of the TRPV1 agonist capsaicin (100 nmol/L and 1 μmol/L; Sigma) or the TRPA1 agonist mustard oil (100 nmol/L and 1 μmol/L; Sigma) diluted in external solution at a rate of ∼1 mL/min. Fluorescence was measured during excitation at 340 and 380 nm, and the ratio of the fluorescence emission at 510 nm was monitored. The baseline was monitored for 120 seconds before perfusion with agonist. Images were acquired every 1 second and processed by using ImageJ (NIH, Bethesda, MD) by drawing discrete regions of interest around cells that responded to KCl (70 mmol/L). Data are expressed as a fold change from baseline fluorescence normalized to background fluorescence (ΔF/F0) on raw traces and were analyzed by using area under the curve.

Microbial Sequencing and Metabolomic Data {#sec3.7}
-----------------------------------------

### 16S rRNA gene amplicon sequencing {#sec3.7.1}

DNA extraction and purification from feces were performed by using QIAamp Fast DNA Stool extraction kit (Qiagen, Toronto, ON, Canada). The V4 hypervariable region of the 16S rRNA gene was amplified by using the following barcoded primers with MiSeq (Illumina, San Diego, CA) -specific adaptors: 16SV4Fwd: AATGATACGGCGACCACCGAGATCTACAC**BARCODE**TATGGTAATTGT GTGCCAGCMGCCGCGGTAA and 16SV4Rev: CAAGCAGAAGACGGCATACGAGAT **BARCODE**AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT. KAPA HiFi polymerase (Roche) was used under the following cycling conditions: initial denaturation 98°C for 2 minutes, 25 cycles of 98°C for 30 seconds, 55°C for 30 seconds, 72°C for 20 seconds, and final elongation at 72°C for 7 minutes. NucleoMag NGS (Macherey-Nagel, Bethlehem, PA) was used for polymerase chain reaction (PCR) cleanup and size selection, followed by PCR product normalization with the SequalPrep Normalization Plate Kit (ThermoFisher, Waltham, MA) according to the manufacturer's protocols. Individual PCR libraries were pooled and then qualitatively and quantitatively assessed on a High Sensitivity D1000 ScreenTape station (Agilent, Waldbronn, Germany) and on a Qubit fluorometer (ThermoFisher). The 16S rRNA v4 gene amplicon sequencing was performed by using a V2-500 cycle cartridge (Illumina) on the MiSeq platform (Illumina).

Raw fastq files were processed by using Cutadapt (version 1.16[@bib89]) and dada2 (R package, version 1.10.1[@bib90]). After removing standard Illumina V4 primers and reads shorter than 50 base pairs, quality filtering was performed by using the filterAndTrim function of dada2, removing reads with an expected error (EE = sum(10ˆ(-Q/10) higher than 2 for both forward and reverse reads. A table of amplicon sequence variants (ASVs) was generated by using the standard dada2 workflow: generating an error model of the data, inferring sequence variants, merging forward and reverse reads, generating a count table, and removing chimeric sequences. Taxonomic classifications were assigned to ASVs by using the dada2::assignTaxonomy function, using the Silva 132 database as a reference.

Liquid Chromatography--Mass Spectrometry Based Short-Chain Fatty Acids Quantification in Mouse Fecal Samples {#sec3.8}
------------------------------------------------------------------------------------------------------------

Samples were processed and analyzed as previously described.[@bib91] In brief, SCFAs were extracted (1:2 ratio wet sample weight \[mg\] to extraction solvent \[μL\]) from fecal samples with ice-cold extraction solvent (50% water/acetonitrile, v/v) spiked with ^13^C-labeled SCFA standards (acetic acid-1,2-13C2, propionic acid-13C3, and butyric acid-1,2-13C2), derivatized with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and aniline, and then submitted to liquid chromatography--mass spectrometry analysis. The UHPLC-MS platform consisted of a Vanquish ultrahigh-performance liquid chromatography system coupled to a TSQ Quantum Access MAX triple quadrupole Mass Spectrometer (Thermo Scientific) equipped with an electrospray ionization probe. In short, SCFAs were separated on a Hypersil GOLD TM C18 column (200 × 2.1 mm, 1.9 μm; Thermo Scientific) by using a binary solvent system composed of liquid chromatography--mass spectrometry grade water and methanol, both containing 0.1% (%v/v) formic acid, and monitored with the mass spectrometer operating in positive ionization mode and selected reaction monitoring mode. Data analyses, on the converted mzXML files, were conducted in MAVEN,[@bib92]^,^[@bib93] and the absolute quantification of native SCFA concentration was based on the ^12^C:^13^C signal intensity ratio and the respective ^13^C-internal standard concentration.

Statistical Analysis {#sec3.9}
--------------------

All data are expressed as the mean ± standard error of the mean. Treatment effects were analyzed by Student *t* test using Prism 7 (GraphPad, La Jolla, CA). Data distribution was tested by using the D\'Agostino and Pearson normality test. One-way or two-way analysis of variance with Bonferroni or Tukey post hoc test was applied for comparison of multiple groups. If the data were found to be not normally distributed, a Kruskal-Wallis test followed by a Dunn multiple comparison or a Mann-Whitney test was used (Prism 7). A *P* value \<.05 was considered to be significant. The 16s rRNA sequencing analysis was carried out by using the R package phyloseq (version 1.24.2[@bib94]). Alpha diversity was estimated by using the Shannon index of diversity, and significance was determined by using a mixed-effects linear model, with treatment and time point as fixed effects and mouse ID as a random effect. Beta diversity was estimated by using a principal coordinates analysis on a matrix of Bray-Curtis distances and analyzed by using permutational multivariate analysis of variance. To test for significant differences in composition at the phylum level, a beta-binomial regression model was performed by using the R package corncob. Differential abundance analysis was carried out by using the R package DESeq2[@bib95] to identify ASVs that were differentially abundant across treatments. ASV counts were modeled by using the negative binomial distribution, and significance was determined by a Wald test on log2 fold change values and an alpha = 0.01. *P* values were adjusted for multiple inference by using the Benjamini-Hochberg method.
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